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ABSTRACT
Intravenous busulfan (IV BU) has demonstrated safety when administered at 0.8 mg/kg per dose IV every 6 hours
 16 doses. We evaluated the safety and pharmacokinetics (PK) of giving the same total daily IV BU dose (3.2 mg/kg)
either divided as a twice-daily infusion or as a single infusion to patients undergoing hematopoietic stem cell trans-
plantation (HSCT). Twelve patients with hematologic malignant disease were treated; 7 patients had non-Hodgkin’s
lymphoma, 4 patients had acute myeloid leukemia, and 1 patient had chronic myelogenous leukemia. The first
cohort (group A) received, on the basis of actual body weight, IV BU at 1.6 mg/kg per dose over 4 hours every
12 hours for 4 days (day –7 to day –4). The second cohort (group B) received 3.2 mg/kg per dose of IV BU (same
total dose as group A) as a single infusion over 4 hours daily for 4 days. In both groups the IV BU was followed by
cyclophosphamide 60 mg/kg daily for 2 days (day –3 and day –2). Blood specimens were collected on the first, fifth,
and seventh doses for group A and on the first and fourth doses for group B to determine the disposition of IV BU.
Peripheral blood stem cells (autologous in 7 cases and HLA-matched allogeneic in 5 cases) were given 2 days after
completion of cyclophosphamide administration (day 0), and granulocyte colony-stimulating factor 5 µg/kg was
started on the same day. GVHD prophylaxis consisted of tacrolimus plus methotrexate for recipients of allogeneic
stem cells. One patient developed presumed fungal pneumonia and died of multisystem organ dysfunction on day
+21 before hematologic reconstitution could be evaluated. Another was reported to have sudden death of undeter-
mined cause at home on day 40. The remaining patients had engraftment (absolute neutrophil count >500/µL) at a
median of 11 days and sustained platelet counts >20,000/µL at a median of 14 days. Significant regimen-related
toxicity (grade III-IV) was limited to hepatic toxicity (2 cases) catheter infection (2 cases), epistaxis (3 cases), diar-
rhea (1 case), anorexia (1 case), mucositis (1 case), hyperglycemia (1 case), pneumonia (1 case), and sepsis (1). In
group B there was 1 case of mild venoocclusive disease, which resolved without sequelae. No central nervous sys-
tem or pulmonary toxicity was noted. Pharmacokinetic parameters, including clearance, half-life, maximum con-
centration, and area under the curve, demonstrated that the first dose profile was highly predictive of later dose
PK profiles. No accumulation of the drug was noted. The change in dosing schedule did not increase toxicity or
end-organ damage despite higher plasma concentration-times. Although further study for long-term efficacy is
warranted, IV BU can be given safely with reproducible results on a twice-daily divided or single-daily dosing
schedule to patients undergoing HSCT.
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INTRODUCTION
Busulfan [1,4-bis-(methanesulfonyloxy)butane] is a
bifunctional alkylating agent ﬁrst described by Haddow and
Timmis [1]. It was initially introduced as palliative therapy
for chronic myeloid leukemia and has been available in the
United States as a 2-mg tablet. The potent antitumor effects
of the drug led Santos and Tutschka to investigate the use of
busulfan to create a murine model of aplastic anemia [2].
This model system was used to introduce high-dose oral
busulfan-based combination chemotherapy for pretransplan-
tation conditioning, most commonly in combination with
cyclophosphamide (BU/CY2). The combination has proved
to be an integral and effective component of conditioning
regimens used in the treatment of patients with hematologic
and nonhematologic malignant diseases who are undergoing
allogeneic or autologous hematopoietic stem cell transplan-
tation (HSCT) [3-9]. The standard oral BU/CY2 regimen
includes administration of busulfan at a dose and schedule of
1.0 mg/kg every 6 hours for a total of 16 doses.
Although busulfan is effective when used in this regi-
men, the therapeutic potential of the drug has been compro-
mised owing to inherent problems associated with oral
administration. Most notable are variable bioavailability and
unpredictable systemic exposure over the course of treat-
ment, primarily because of erratic absorption [10,11]. Phar-
macokinetic (PK) monitoring of busulfan has been used in
an effort to address this variability; however, PK data cannot
be obtained for up to 25% of patients because of delayed
absorption and/or elimination and for a number of patients
who have vomited all or part of the intended drug dose [12].
The erratic levels have contributed to variations in systemic
busulfan concentration. The variation in concentration leads
to increased risk of toxicity due to overexposure [12,13] or
to increased risk of graft failure and/or leukemic relapse due
to suboptimal drug levels [14].
Andersson et al. [15], using dimethyl acetamide and
polyethylene glycol 400, developed a soluble formulation of
busulfan that became commercially available in 1999. This
pharmaceutically acceptable formulation allowed for a stable
dissolved drug that could be diluted further in either normal
saline or 5% dextrose in water and delivered parenterally
with 100% bioavailability [15,16]. The published data from
the phase I trial determined the dose of 0.8 mg/kg body
weight to yield PK parameters similar to those obtained
after a standard oral dose of 1 mg/kg body weight [17].
These PK data were supported in a recently completed
phase II trial [18] in which patients with advanced hemato-
logic malignant disease were treated with 16 doses of intra-
venous (IV) BU at 0.8 mg/kg every 6 hours followed by
2 daily doses of cyclophosphamide at 60 mg/kg IV. The reg-
imen was well tolerated, and the safety and efﬁcacy of the
dose and regimen were confirmed. Data from this trial
demonstrated a more consistent dosing and PK proﬁle than
that reported with use of oral busulfan [12].
Unlike other alkylating agents, busulfan is not cell-cycle
speciﬁc. Most alkylating agents are dosed on a daily sched-
ule. In the case of busulfan, because of the availability of only
2-mg tablets, investigators in the initial clinical studies pre-
scribed divided busulfan doses administered every 6 hours to
improve patient compliance (P. Tutschka, personal commu-
nication, 1999). Alternate dosing of busulfan has been inves-
tigated. Preclinical data are available on once-daily dosing in
animal models [19,20]. In the treatment of children, busulfan
has been given orally as a daily dose without increased toxic-
ity [21]. Daily dosing and twice-daily dosing schedules of
busulfan have been investigated in the adult population;
however, there is a lack of PK data on these schedules.
In this study we evaluated administration of IV BU in a
modiﬁed IV BU/CY2 regimen in the treatment of patients
with hematologic malignant disease undergoing HSCT.
The PK and safety proﬁles associated with these schedules
were evaluated, and initial ﬁndings are presented.
METHODS
Protocol Eligibility
Written informed consent was obtained from all partici-
pants in the study. The protocol was approved by the
University of Miami Medical Sciences Committee for the
Protection of Human Subjects in Research. The study
allowed for enrollment of patients 16 to 65 years of age with
advanced hematologic malignant disease who were candi-
dates for HSCT. Five of the 12 patients were at high risk of
transplantation-related complications due to persistent or
refractory disease. Patient entry criteria included adequate
cardiac (left ventricular ejection fraction, >40%), renal
(glomerular ﬁltration rate, >50 mL/min), and hepatic func-
tion (transaminase levels, <1.5 times normal). Peripheral
blood stem cell collection had to contain at least 4 × 106
CD34+ cells per kilogram for allogeneic transplantation and
more than 1 × 106 CD34+ cells per kilogram for autologous
transplantation.
Conditioning Regimen
Group A received IV BU (Busulfex, Orphan Medical,
Minnetonka, MN) at 1.6 mg/kg every 12 hours for 8 doses
from days –7 to day –4. Group B received IV BU 3.2
mg/kg (same total dose) daily for 4 days. The dose of IV
BU for both groups was based on actual body weight and
was administered in a controlled-rate infusion over 4
hours. The IV BU was followed by cyclophosphamide 60
mg/kg IV over 4 hours daily for 2 days, days –3 and –2, to
both groups. All patients were given seizure prophylaxis
with phenytoin from day –8 to day –3; doses were adjusted
to a therapeutic level of 10-20 µg/mL. After a day of rest,
the autologous or allogeneic peripheral blood stem cells
were infused on day 0 and followed by granulocyte colony-
stimulating factor 5 µg/kg IV starting on the same day.
Patients who received allogeneic peripheral blood stem
cells received graft-versus-host disease (GVHD) prophylaxis
consisting of tacrolimus 0.03 mg/kg daily as a continuous IV
infusion and then switched to oral dosing of 0.12 mg/kg per
day in divided doses. In addition, methotrexate was given at
10 mg/m2 on day 1 and at 5 mg/m2 on days 3, 6, and 11 post-
transplantation. Standard support based on our unit policies,
including antibiotics and blood transfusion, was provided to
the patients in the posttransplantation period.
Pharmacokinetic Sampling and Analysis
In group A, blood samples from a peripheral line were
drawn on doses 1 and 7 of the IV BU therapy according to
the following schedule: predose and 1.5, 2, 3.5, 4, 4.5, 5.5, 7,
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9, 11, and 12 hours from the start of IV BU infusion. Peak
and trough levels were measured on dose 5 for quality con-
trol. Group B had samples drawn on doses 1 and 4 at the
following time points: predose and 1.5, 3, 4, 5, 6, 8, 10, 12,
15, and 18 hours from the start of infusion.
Blood samples were collected in ice-chilled heparinized
Vacutainer tubes and plasma separated within 12 hours by
centrifugation at 1000g for 10 minutes at 4°C. Plasma samples
were stored frozen at –80°C until analysis. The analysis for
busulfan was performed with a validated high-performance
liquid chromatography assay as described elsewhere [14,22].
IV BU peak concentration (Cmax) is an observed value. The
IV BU area under the plasma concentration versus time curve
(AUC) per IV BU dose was calculated by dividing the drug
dose by the IV BU plasma clearance (CL) estimate. All PK
modeling was performed with ADAPT II software, version
4.0 (BMSR, University of Southern California, Los Angeles,
CA) [23]. For group A, the ﬁfth-dose IV BU plasma CL was
determined by modeling IV BU plasma concentration versus
time data from dose 1 and dose 5. The seventh-dose IV BU
plasma CL was determined by modeling all (doses 1, 5, and 7)
data. For group B, the fourth-dose IV BU plasma CL was
determined by modeling IV BU plasma concentration versus
time data from dose 1 and dose 4.
Monitoring
Patients were monitored in 3 different periods. Condi-
tioning was deﬁned as from the start of chemotherapy to the
day of transplantation. The early posttransplantation period
was day 1 to day 28, and the late posttransplantation period
was day 28 to day 100. Patient toxicity was monitored with
the National Cancer Institute common grading criteria [24].
The Jones criteria [25] were used for standardized evaluation
of venoocclusive disease (VOD). GVHD was graded accord-
ing to established criteria [26]. Engraftment of neutrophils
was defined as an absolute neutrophil count >500/µL for
3 consecutive days. Platelet engraftment was defined as a
self-sustained platelet count of 20,000/µL for 3 consecutive
days. Relapse was deﬁned as documentation of progressive
disease based on reappearance of greater than 5% blasts in
the peripheral blood or in the bone marrow (leukemia) or
clinical or radiographic growth or progression of lymph
nodes (lymphoma or Hodgkin’s disease) posttransplantation.
RESULTS
Patient Characteristics
Table 1 notes the patient characteristics. The median
age of the patients was 52 years (range, 26 to 65 years).
Seven patients underwent autologous transplantation: 5 for
non-Hodgkin’s lymphoma (NHL) and 2 for acute myeloid
leukemia (AML). Five patients underwent allogeneic trans-
plantation: 2 for AML, 2 for NHL, and 1 for chronic myelo-
genous leukemia (CML). Six of the patients were in complete
remission (CR) at the time of transplantation, and 2 patients
had a partial response (PR) at the time of transplantation.
Three patients had relapsed/refractory AML. The patient
with CML was in chronic phase.
Busulfan Pharmacokinetics
Results of the PK evaluation are shown in Table 2. For
all the patients the PK data showed minimal intrapatient
variation for AUC, half-life (t1/2), CL, or Cmax of busulfan.
Intrapatient variability ranged from less than 1% to 10%.
The median AUC for group A (twice-daily dosing) was
3390 µM*min (range, 2400-4678 µM*min). IV BU infusion
gave consistent PK with little change in t1/2, CL, or Cmax on
the seventh dose. The fifth dose showed results similar to
those with both the ﬁrst and the seventh dose, although only
peak and trough levels were measured. Figure 1 shows a
representative PK plot comparison of doses 1 and 7 that
demonstrates a very tight proﬁle from dose to dose.
Group B (once-daily dosing) also had similar intrapatient
results with small (<10%) variation between doses. Although
the Cmax was higher in this group, the CL of the drug
remained the same as that seen with twice-daily dosing. The
AUC fell within the expected values for this dose with a
median AUC of 5561 µM*min (range, 4414-7368 µM*min).
Figure 2 shows a representative PK plot comparison of the
AUC for ﬁrst and fourth doses of a patient in group B.
Table 1. Patient Characteristics*
Status at Response at
Patient Type Age Diagnosis Transplantation 100 Days
Group A: Twice daily
1 Auto 65 NHL CR CR
2 Allo 60 AML Relapse Died
3 Auto 43 NHL CR CR
4 Auto 49 NHL PR CR
5 Auto 55 NHL CR CR
6 Allo 26 CML Chronic CR
Group B: Daily
7 Auto 51 AML CR2 PD
8 Auto 36 NHL CRU2 CR
9 Auto 47 AML Refractory PD
10 Allo 37 NHL/AML PR/CR CR
11 Allo 42 NHL CR3 CR
12 Allo 49 AML Refractory Died
*Auto indicates autologous; allo, allogeneic; CR2, second CR; PD, progressive disease; CRU2, second complete remission undetermined; CR3,
third CR. 
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Toxicity
Table 3 shows the toxicity proﬁle for the patients during
conditioning and to the first 28 days posttransplantation.
The majority of toxicity was grade 1 and 2, including nau-
sea, vomiting, diarrhea, fatigue, and insomnia. Grade 3 toxi-
city included mucositis in 1 patient, anorexia in 1 patient,
infection in 2 patients, pneumonia in 1 patient, epistaxis in
2 patients, and hyperglycemia in 1 patient. One patient in
group A, who received an allogeneic transplant, developed
grade 4 toxicity and died of sepsis, presumed fungal infec-
tion, and multiple-system organ failure. One patient in
group B was discharged to home after transplantation. On
day 40 posttransplantation, he had sudden death of undeter-
mined cause; autopsy was not performed.
Hepatic abnormalities (elevated bilirubin level) were
seen in 2 patients. The median total bilirubin level was
1.1 mg/dL (range, 0.7-2.6 mg/dL). One of the patients with
hepatic abnormalities developed clinical VOD on day 23
after starting medroxyprogesterone acetate. The process
resolved, when the drug was discontinued, by day 43.
Transaminase levels, with the exception of the patient who
developed VOD, never rose above 3 times normal.
Overall, the toxicity profile was similar to that previ-
ously reported in the every-6-hour dosing of IV BU trials
[17,18]. No new or unexpected toxicities were noted in
these patients. All observed side effects had been previously
described after various myeloablative conditioning programs
[6-9]. Evaluation from the late posttransplantation period
(days 28 to 100) showed no new adverse events and recov-
ery of all grade 3 toxicity, including previously noted liver
toxicity. All 4 evaluable allogeneic transplantation patients
developed grade I to II acute GVHD (1 patient, grade I;
Table 2. Pharmacokinetics of Twice-Daily and Daily IV Busulfan Dosing*
Patient Dose No. Weight, kg Dose, mg AUC, µM*min t1/2, h CL, mL/min per kg Cmax, µg/mL
Group A: Twice daily
1 1 66 105 3418 3.64 1.89 2.10
5 3280 3.20 1.97 2.35
7 ND ND ND ND
2 1 108 174 4678 3.41 1.40 2.56
5† 4513 3.37 1.45 2.31
7 4580 3.39 1.43 2.95
3 1 106 170 3108 2.95 2.10 1.99
5† 3115 2.98 2.09 2.15
7 3203 3.15 2.04 2.22
4 1 106 170 4214 3.10 1.55 2.45
5† 4309 3.13 1.51 3.18
7 4561 3.20 1.43 3.10
5 1 78.5 125 3375 3.89 1.92 1.85
5† 3405 3.96 1.90 1.98
7 3191 3.66 2.03 1.87
6 1 80.5 128 2662 3.78 2.43 1.75
5 ND ND ND ND
7 2400 3.32 2.69 1.66
Median 3390 3.35 1.91 2.19
Group B: Daily
7 1 102.6 278‡ 7368 3.20 1.49 4.36
4 7127 3.18 1.55 4.56
8 1 86.5 237‡ 4577 2.32 2.43 4.06
4 4414 2.33 2.52 3.50
9 1 68.4 218 6075 2.34 2.13 4.42
4 5898 2.40 2.20 4.10
10 1 81.2 256 5583 2.35 2.30 3.80
4 5538 2.39 2.31 3.70
11 1 68.8 226 5117 3.11 2.61 3.50
4 5297 2.97 2.52 3.60
12 1 70.7 227 5289 2.77 2.47 3.60
4 5813 2.80 2.75 3.00
Median 5561 2.59 2.37 3.75
*ND indicates not done.
†Results based on peak and trough levels only.
‡Dosed at 0.85 of actual body weight because of obesity.
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3 patients, grade II) prior to day 100. There were no seizures
or delayed pulmonary toxicity. No new transplantation-
related toxicity developed. No new unexpected toxicity or
sequelae from the treatment regimen were noted in the
patients past day 100 of the study.
Outcomes
Patients were evaluated for engraftment and disease
response to day 100. The 11 evaluable patients had engraft-
ment at a median of 11 days (range, 10-20 days). Platelet
levels were self-sustained at >20,000/µL at a median of 14 days
(range, 11-23 days) (Table 4). These results were compara-
ble to our prior experience with the oral and IV BU/CY2
regimen of every-6-hour dosing schedules. Engraftment,
based on peripheral blood counts (autologous patients) and
bone marrow cytogenetic evaluation (allogeneic patients),
was stable past day 100. Eight of 10 evaluable patients in
this small cohort attained CR by day 100. The 2 patients
with AML, who received autologous transplants, had clear-
ance of circulating blasts but developed disease progression
prior to day 100.
DISCUSSION
To date, studies of the IV BU formulation we used have
demonstrated highly consistent and reproducible PK
whether the dosing was every 6 hours [18] or, as in our
study, every 12 hours [27] or 24 hours. There has been
repeated demonstration of minimal intrapatient variability
in the disposition of IV BU, as shown in the PK parameters,
including AUC, CL, Cmax, and t1/2 of this drug. The PK
proﬁle of the ﬁrst dose can be a predictor of the later con-
centrations of the drug.
The total busulfan AUC in our study shows a slightly
higher than expected cumulative AUC for group A. This
effect may have been due to dosing on actual body weight
rather than adjusting the dose for the obese patients. In
group B, the 2 obese patients had a slight adjustment of the
dose (0.85 of actual body weight), and the result was expo-
sure closer to the expected level. If the AUC (Table 2) for
patients in group A is multiplied by 8 and the AUC of group
B is multiplied by 4 (number of doses per group), the range
for the total AUC is 17,056 to 37,420 µM*min, the median
being 24,682 µM*min. These results are in a range previ-
ously seen in studies with both oral [12,13] and IV [18] dos-
ing of busulfan. All the busulfan AUC values were above the
accepted minimal level for efficacy of the drug previously
mentioned by Slattery et al. [14].
Excessive exposure to busulfan has been associated with
higher morbidity and mortality [28], which include central
nervous system toxicity [29]. Despite the high systemic peak
levels (Cmax) of the drug, there was no new unexpected or
unusual toxicity in our patients. Our study demonstrated
levels above the reported “safety level” of the drug concen-
tration. With an every-6-hour dosing schedule, patients
with AUC values greater than 24,000 µM*min are more
Figure 1. Example of busulfan concentration curves of the ﬁrst, ﬁfth,
and seventh doses in a patient receiving twice-daily dosing.
Figure 2. Example of busulfan concentration curves of the ﬁrst and
fourth dose in a patient receiving daily dosing.
Table 3. Transplantation-Related Toxicity for Twice-Daily and Daily Dosing*
Grade
Type 1 2 3 4 Total
Nausea 12 0 0 0 12
Diarrhea 11 0 1 0 12
Vomiting 8 3 0 0 11
Mucositis 3 6 1 0 9
Fatigue 8 1 0 0 9
Insomnia 8 1 0 0 9
Anorexia 5 2 1 0 9
Headache 6 1 0 0 7
Anxiety 7 0 0 0 7
Infection 2 1 2 0 5
Epistaxis 1 0 3 0 4
Pulmonary 2 1 1 0 4
Hepatic 0 1 2† 0 3
Sepsis 0 0 0 1 1
Hyperglycemia 0 0 1 0 1
Central nervous system disorder 0 0 0 0 0
*Based on National Cancer Institute common toxicity criteria.
†Includes one case of hepatic VOD.
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prone to hepatic VOD [12,13]. Six of the 12 patients (5 in
group A, 1 in group B) in our study were above this thresh-
old. Despite this ﬁnding, only 1 patient developed VOD in
our study. This patient was well within the expected AUC
range and may have had the process triggered by the admin-
istration of medroxyprogesterone.
The lack of VOD in the patients with higher AUC levels
may be explained several ways. First, the use of IV BU cir-
cumvents the ﬁrst-pass hepatic effect. Because less of the drug
passes through the liver initially, there is less depletion of the
glutathione stores. Results of a recent retrospective analysis
comparing oral to IV BU support this theory [30]. Second,
the use of twice-daily and daily dosing may have allowed for
glutathione-S-reductase and glutathione-S-transferase recov-
ery between doses. Even if stores were depleted with each
dose, the delay of the next dose would allow more recovery of
the enzymes. In addition, at the end of the 24-hour dosing
interval, there were minimally detectable busulfan levels in
patients receiving the IV BU daily dosing. Finally, the time
separation from the last dose of busulfan to the ﬁrst dose of
cyclophosphamide may contribute to reduce hepatic injury, as
has been previously suggested [10,14].
There was no increase in tissue injury to the lungs, kid-
neys, heart, or liver as evidenced by results of serologic
monitoring of surrogate end points (ie, creatinine, lactate
dehydrogenase, and liver function tests). In our study there
were no seizures or other central nervous system abnormali-
ties. The higher concentrations had no effect on engraft-
ment of the neutrophils or platelets. Median times to
engraftment were similar to those seen historically at our
center and to prior results with every-6-hour IV BU [18].
The reproducible PK proﬁle of IV BU is in stark con-
trast to the erratic and unpredictable PK values experienced
with oral busulfan [12,31,32]. IV BU should allow for strate-
gies with a test dose to predict a target AUC. The predict-
ability of the drug also allows for a less frequent PK testing
schedule and possibly the use of a more limited sampling set
to be used for PK evaluation. The collection of 4 or 5 sam-
ples on the ﬁrst dose has been validated in an every-6-hour
schedule. It determines busulfan concentrations adequately
to gather necessary PK information and allows for dose
adjustments if needed [33].
Our study provides evidence that twice-daily and daily
dosing of IV BU appears to be safe with reproducible and
favorable PK. Based on the PK proﬁle, this strategy allows a
consistent and accurate busulfan delivery at all dosing
points. The results of this study suggest that twice-daily or
daily dosing of IV BU and daily cyclophosphamide can be
used as a pretransplantation conditioning regimen for
patients with advanced hematologic malignant disease.
Although we are encouraged by our preliminary results, we
feel that further evaluation of both these dosing regimens,
including PK studies and long-term efﬁcacy, is warranted.
ACKNOWLEDGMENTS
This study was supported in part through an unrestricted
educational grant from Orphan Medical, Inc. (OMI). Dr.
Hugo F. Fernandez is an educational speaker for OMI.
The authors would like to acknowledge the excellent
work of the clinical nursing staff, research nurses, and data
monitors of the University of Miami Jackson Memorial
Medical Center/Sylvester Comprehensive Cancer Center
Blood and Marrow Transplant program, without whom this
project would have been impossible.
REFERENCES
1. Haddow A, Timmis GM. Myleran in chronic myeloid leukemia.
Lancet. 1953;1:207-208.
2. Santos GW, Tutschka PJ. Marrow transplantation in the busul-
fan-treated rat: preclinical model of aplastic anemia. J Natl Cancer
Inst. 1974;53:1781-1785.
3. Santos GW, Tutschka PJ, Brookmeyer R, et al. Marrow trans-
plantation for acute nonlymphocytic leukemia after treatment
with busulfan and cyclophosphamide. N Engl J Med. 1983;309:
1347-1353.
4. Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation
for leukemia following a new busulfan and cyclophosphamide reg-
imen. Blood. 1987;70:1382-1388.
5. Geller RB, Saral R, Piantadosi S, et al. Allogeneic bone marrow
transplantation after high-dose busulfan and cyclophosphamide in
patients with acute nonlymphocytic leukemia. Blood. 1989;73:
2209-2218.
6. Weaver CH, Schwartzberg L, Rhinehart S, et al. High-dose
chemotherapy with BuCY or BEAC and unpurged peripheral
blood stem cell infusion in patients with low-grade non-Hodgk-
in’s lymphoma. Bone Marrow Transplant. 1998;21:383-389.
7. Ringden O, Labopin M, Tura S, et al. A comparison of busulfan
versus total body irradiation combined with cyclophosphamide as
conditioning for autograft or allograft bone marrow transplanta-
tion in patients with acute leukemia. Acute Leukemia Working
Party of the European Group for Blood and Marrow Transplan-
tation (EBMT). Br J Haematol. 1996;93:637-645.
8. Devergie A, Blaise D, Attal M, et al. Allogeneic bone marrow
transplantation for chronic myeloid leukemia in first chronic
phase: a randomized trial of busulfan-cytoxan versus cytoxan-
total body irradiation as preparative regimen; a report from the





Patient ANC, d Platelets, d mg/dL U/L U/L
1 10 11 0.7 41 37
2 NE NE 2.6 37 23
3 12 14 0.8 96 130
4 11 12 1.9 59 52
5 10 12 1.3 60 105
6 12 13 1.2 55 119
7 8 15 0.7 43 51
8 13 17 0.9 58 93
9 10 13 1.5 2190 1058
10 11 17 0.8 62 162
11 10 14 0.8 150 264
12 20 23 2.2 34 42
Median 11 14 1.1 60 112
*ANC indicates absolute neutrophil count; AST, aspartate amino-
transferase; ALT, alanine aminotransferase; NE, not evaluable.
H. F. Fernandez et al.
492
French Society of Bone Marrow Graft (SFGM). Blood. 1995;85:
2263-2268.
9. Blume KG, Kopecky KJ, Henslee-Downey JP, et al. A prospective
randomized comparison of total body irradiation-etoposide versus
busulfan/cyclophosphamide as preparative regimens for bone
marrow transplant in patients with leukemia who were not in ﬁrst
remission: a Southwest Oncology Group study. Blood. 1993;81:
2187-2193.
10. Hassan M, Ljungman P, Bolme P, et al. Busulfan bioavailability.
Blood. 1994;84:2144-2150.
11. Schuler U, Schroer S, Kühnle A, et al. Busulfan pharmacokinetics
in bone marrow transplant patients: is drug monitoring war-
ranted? Bone Marrow Transplant. 1994;14:759-765.
12. Dix SP, Wingard JR, Mullins RE, et al. Association of busulfan
area under the curve with veno-occlusive disease following BMT.
Bone Marrow Transplant. 1996;17:225-230.
13. Grochow LB, Jones RJ, Brundrett RB, et al. Pharmacokinetics
and busulfan: correlation with veno-occlusive disease in patients
undergoing bone marrow transplantation. Cancer Chemother Phar-
macol. 1989;25:55-61.
14. Slattery JP, Sanders JE, Buckner CD, et al. Graft rejection and tox-
icity following bone marrow transplantation in relation to busulfan
pharmacokinetics. Bone Marrow Transplant. 1995;16:31-42.
15. Andersson BS, Bhagwatwar H, Chow D. Parenteral Busulfan for
treatment of malignant disease. US patents 5,430,057, 1995, and
5,559,148, 1996.
16. Bhagwatwar H, Phadungponja S, Chow D, et al. Formulation and
stability of busulfan for intravenous administration in high-dose
chemotherapy. Cancer Chemother Pharmacol. 1996;37:401-408.
17. Andersson BS, Madden T, Tran HT, et al. Acute safety and phar-
macokinetics of intravenous busulfan when used with oral busulfan
and cyclophosphamide as pre-transplantation conditioning ther-
apy: a phase I study. Biol Blood Marrow Transplant. 2000;6:548-554.
18. Andersson BS, Ashwin K, Gian V, et al. Conditioning therapy with
intravenous busulfan and cyclophosphamide (IV BuCy2) for hema-
tological malignancy prior to allogeneic stem cell transplantation: a
phase II study. Biol Blood Marrow Transplant. 2002;8:145-154.
19. Dix SP, Bucur SZ, Mullins RE, et al. Studies of the pharmacoki-
netics and toxicity of once daily bolus intravenous busulfan in non-
human primates [abstract]. Blood. 1995;86(suppl 1). Abstract 888.
20. Deeg HJ, Schuler VS, Shulman H, et al. Myeloablation by intra-
venous busulfan and hematopoietic reconstitution with autolo-
gous marrow in a canine model. Biol Blood Marrow Transplant.
1999;5:316-321.
21. Shaw PJ, Scharping CE, Brian RJ, Earl JW. Busulfan pharmaco-
kinetics using a single daily high-dose regimen in children with
acute leukemia. Blood. 1994;84:2357-2362.
22. Tran HT, Madden T, Petropoulos D, et al. Individualizing high-
dose oral busulfan: prospective dose adjustment in a pediatric
population undergoing allogeneic stem cell transplantation for
advanced hematologic malignancies. Bone Marrow Transplant.
2000;26:463-470. 
23. D’Argenio DZ, Schumitzky A. A program package for simulation
and parameter estimation in pharmacokinetics. Comput Programs
Biomed. 1979;9:115-134.
24. Common Toxicity Criteria. Version 2.0. Available at: http://ctep.
info.nih.gov/reporting/ctc.html.
25. Jones RJ, Lee KS, Beschorner WE, et al. Venocclusive disease of
the liver following bone marrow transplantation. Transplantation.
1975;44:778-783.
26. Thomas ED, Storb R, Clift RA, et al. Bone-marrow transplanta-
tion. N Engl J Med. 1975;292:832-843, 895-902.
27. Fernandez HF, Tran HT, Albrecht F, et al. Evaluation of safety,
efficacy and pharmacokinetics of administering IV busulfan
(Busulfex®) in patients with advanced hematologic malignancies
undergoing stem cell transplant (SCT) [abstract]. Biol Blood
Marrow Transplant. 2001;7:71. Abstract 29.
28. Ljungman P, Hassan M, Bekassy AN. High busulfan concentra-
tions are associated with increased transplant-related mortality in
allogeneic bone marrow transplant patients. Bone Marrow Trans-
plant. 1997;20:909-913.
29. Vassal G, Deroussent A, Hartmann O, et al. Dose-dependent
neurotoxicity of high-dose busulfan in children: a clinical and
pharmacological study. Cancer Res. 1990;50:6203-6207.
30. Kashyap A, Wingard J, Cagnoni S, et al. Intravenous (IV) vs. oral
busulfan (BU) as part of Bu/Cy (cyclophosphamide) preparative
regimen for allogeneic hematopoietic stem cell transplantation
(HSCT): decreased incidence of hepatic veno-occlusive disease
(VOD) [abstract]. Blood. 1999;94(suppl 1):321b. Abstract 4661.
31. Lindley C, Shord S, McCune J, et al. Test dose and traditional
ﬁrst dose therapeutic drug monitoring for busulfan (BU) fail to
accurately predict steady-state systemic exposure in allogeneic
bone marrow transplantation patients. Proc Am Soc Clin Oncol.
2001;20:9a. Abstract 31.
32. Bolinger A, Zangwill A, Slattery J, et al. Target dose adjustment
of busulfan using pharmacokinetic parameters in pediatric
patients undergoing bone marrow transplantation for malig-
nancy or genetic disease [abstract]. Blood. 1999;94(suppl 1):145a.
Abstract 635.
33. Vaughan W, Carey D, Salzman D, Soong S. Validation of a lim-
ited sampling strategy (LSS) for pharmacokinetically directed
dosing of high-dose intravenous busulfan (Busulfex) in BMT
preparative regimens [abstract]. Biol Blood Marrow Transplant.
2001;7:92. Abstract 106.
